Brought to you by 
Merck, Alnylam end RNAi agreement for ophthalmic drugs
Jul 2004
Executive Summary
Merck & Co. and Alnylam Pharmaceuticals (therapeutics based on RNA interference) have signed a multi-year agreement covering the development and marketing of RNAi drugs (particularly VEGF inhibitors) to treat ocular diseases.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Includes Contract
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com